a total of 22 immunocompromised patients undergoing treatment for hematologic malignancies and presenting with vzv infection within 72 hours of the onset of rash were randomly assigned to receive intravenous acyclovir or vidarabine ;
C0008049
vzv infection
C0001367
acyclovir